Processa Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
Processa Pharmaceuticals, Inc. (PCSA) reported Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent of 2.32% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes · last filed 2026-03-18
- Processa Pharmaceuticals, Inc. effective income tax rate reconciliation, state and local income taxes, percent for fiscal 2025 was 2.32%, a 44.36% decline from fiscal 2024.
- Processa Pharmaceuticals, Inc. effective income tax rate reconciliation, state and local income taxes, percent for fiscal 2024 was 4.17%, a 27.73% decline from fiscal 2023.
- Processa Pharmaceuticals, Inc. effective income tax rate reconciliation, state and local income taxes, percent for fiscal 2023 was 5.77%, a 0.87% increase from fiscal 2022.
- Processa Pharmaceuticals, Inc. effective income tax rate reconciliation, state and local income taxes, percent for fiscal 2022 was 5.72%, a 9.37% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent 12 month | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 2.32% 10-K · filed 2026-03-18 | |
| 2024-12-31 | 4.17% 10-K · filed 2026-03-18 | 5.58% 10-K · filed 2025-03-20 |
| 2023-12-31 | 5.77% 10-K · filed 2025-03-20 | |
| 2022-12-31 | 5.72% 10-K · filed 2024-03-29 | |
| 2021-12-31 | 5.23% 10-K · filed 2023-03-30 | 1.05% 10-K · filed 2022-03-30 |
| 2020-12-31 | 1.54% 10-K · filed 2022-03-30 | |
| 2019-12-31 | 3.60% 10-K · filed 2021-03-25 | |
| 2018-12-31 | 4.58% 10-K · filed 2020-03-06 | |
| 2017-12-31 | 5.45% 10-K/A · filed 2019-04-08 | |
| 2016-12-31 | 0.00% 10-K · filed 2018-04-16 | 5.70% 10-K · filed 2017-09-25 |
| 2015-12-31 | 7.10% 10-K · filed 2017-09-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |